List view / Grid view
6 May 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc., announced the results of its landmark PRIDE trial...
6 May 2014 | By Novartis
Novartis presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR in patients with acromegaly for whom current standard of care provides inadequate disease control...
6 May 2014 | By Boehringer Ingelheim
Connexios Life Sciences and Boehringer Ingelheim announced an exclusive global research collaboration agreement for AMPK agonists for the treatment of patients with Type 2 Diabetes...
6 May 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia...
6 May 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer and metastatic renal cell carcinoma will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology...
2 May 2014 | By Merck
Merck and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped...
2 May 2014 | By The European Medicines Agency
The European Medicines Agency has presented the European Commission with its first report on the tasks it undertook during the first year of application of the EU’s new pharmacovigilance legislation...
1 May 2014 | By Novo Nordisk
7% sales growth in local currencies driven by Levemir® and Victoza®...
1 May 2014 | By Biogen Idec
Biogen Idec announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI® (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis patients with confirmed improvement in walking speed...
1 May 2014 | By Nova Laboratories
UK pharmaceutical firm Nova Laboratories has secured U.S Food and Drug Administration approval for its acute lymphoblastic leukaemia (ALL) product Xaluprine...
30 April 2014 | By Teva
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties...
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
30 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim Animal Health reinforces its commitment to support applied research for the improved control of PRRS (Porcine Reproductive and Respiratory Syndrome) in Europe...
30 April 2014 | By Biogen Idec
Additional real-world data show tolerability profile consistent with pivotal studies...
30 April 2014 | By Waters
Powerful alternative to LIMS offers seamless lab-to-business connection for science-driven organizations...
